Catecholaminergic Polymorphic Ventricular Tachycardia
The Catecholaminergic Polymorphic Ventricular Tachycardia Panel examines 9 genes associated with hereditary catecholaminergic polymorphic ventricular tachycardia (CPVT).
Who is this test for?
Patients with a personal and/or family history suggestive of CPVT. CPVT is defined by ventricular rhythm problems, including bidirectional and polymorphic ventricular tachycardia and ventricular fibrillation. Red flags for CPVT can include, but are not limited to, light-headedness, dizziness, fainting, seizures, unexplained cardiac arrest, or sudden death, especially during exercise. Symptoms typically begin in childhood.
What are the potential benefits for my patient?
Patients identified with CPVT can benefit from increased surveillance and preventative steps to better manage their risks. Medical intervention can include beta blockers, calcium channel-blockers, and lifestyle changes. Also, your patient’s family members can be tested to help define their risk. If a pathogenic variant is identified in your patient, close relatives (children, siblings, parents) could have as high as a 50% risk to also be at increased risk. In some cases, screening should begin in childhood.